Ecofucin, 100 mg 20 pcs

Indications
intestinal candidiasis;
acute pseudomembranous and acute atrophic candidiasis in patients with cachexia, immune deficiency, as well as after therapy with antibiotics, corticosteroids, cytostatics;
sanitation of the intestinal reservoir of fungi of the genus Candida for candidiasis of the skin and mucous membranes, incl. for candidiasis vaginitis, vulvitis, vulvovaginitis.

Indications

intestinal candidiasis;
acute pseudomembranous and acute atrophic candidiasis in patients with cachexia, immune deficiency, as well as after therapy with antibiotics, corticosteroids, cytostatics;
sanitation of the intestinal reservoir of fungi of the genus Candida for candidiasis of the skin and mucous membranes, incl. for candidiasis vaginitis, vulvitis, vulvovaginitis.

Pharmacological effect

Pharmacotherapeutic group: Antifungal agent.

ATX code: A07AA03.

Pharmacological properties

Pharmacodynamics

Antifungal polyene (tetraene) antibiotic of the macrolide group. It has a predominantly fungicidal effect. Natamycin irreversibly binds to ergosterol of the cell membrane of the fungal cell, which leads to a violation of its integrity, loss of cytoplasmic contents and cell death. Most pathogenic yeasts and molds are sensitive to natamycin, including the genera Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium. Dermatophytes and P. boydii are less sensitive to natamycin. There are no cases of resistance to natamycin in clinical practice. Natamycin in the dosage form of enteric tablets acts only in the intestinal lumen.

Pharmacokinetics

Natamycin is not absorbed from the gastrointestinal tract and does not have a systemic effect.

Special instructions

Patients with rare congenital intolerance to galactose, fructose, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase deficiency should take into account that the drug contains lactose monohydrate.

If you have one of the listed diseases, be sure to consult your doctor before taking the drug.

Ecofucin® in this dosage form is not recommended for use in infants due to possible difficulty swallowing tablets.

Impact on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Natamycin

Composition

Composition per tablet

Active ingredient:
natamycin (calculated as 100% substance) – 100.00 mg.

Excipients:
potato starch – 76.50 mg,
povidone K-17 – 13.00 mg,
magnesium stearate – 2.50 mg,
lactose monohydrate – to obtain an uncoated tablet weighing 250.00 mg.

Shell excipients:
methacrylic acid and ethyl acrylate copolymer (1:1) – 9.29 mg,
talc – 5.52 mg,
povidone K-25 – 2.51 mg,
macrogol-4000 – 1.42 mg,
titanium dioxide – 1.26 mg.

Pregnancy

The drug can be used during pregnancy and breastfeeding.

Contraindications

Hypersensitivity to the components of the drug. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Side Effects

From the digestive system: nausea and diarrhea are possible, occurring in the first days of taking the pills and going away on their own during treatment.

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

No interaction of Ecofucin® with other drugs has been detected.

Overdose

No cases of overdose of Ecofucin® have been reported.

Storage conditions

In the original packaging (pack) at a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

2 years.
Do not use after the expiration date indicated on the package.

Manufacturer

ABVA RUS, Russia